Truist Financial analyst Asthika Goonewardene reiterated a Buy rating on Arcellx Inc (ACLX – Research Report) today and set a price target of $136.00. The company’s shares closed yesterday at ...
Arcellx (NASDAQ:ACLX – Free Report) had its price target raised by Piper Sandler from $91.00 to $115.00 in a report issued ...
Zacks.com on MSN5d
Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar?Arcellx (ACLX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
Arcellx (NASDAQ:ACLX) announced an update for its Phase 3 iMMagine-3 study and plans to present Phase 1 and 2 data for its ...
BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.
Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...
Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2024 investor letter. A ...
Zacks.com on MSN4d
Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year?For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Arcellx, Inc. (ACLX) one of those stocks right now? A quick ...
Truist Securities analyst Asthika Goonewardene in an investor note said data for anito-cel—particularly its safety ...
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with ...
Leerink Partners analyst Daina Graybosch has maintained their bullish stance on ACLX stock, giving a Buy rating on November 8. Daina ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback